BAYND Stock Overview
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Bayer Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €27.32 |
| 52 Week High | €60.76 |
| 52 Week Low | €24.99 |
| Beta | 0.97 |
| 1 Month Change | 1.96% |
| 3 Month Change | -15.60% |
| 1 Year Change | -54.80% |
| 3 Year Change | -49.65% |
| 5 Year Change | -54.00% |
| Change since IPO | -48.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| BAYND | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 4.0% | 3.3% | 2.7% |
| 1Y | -54.8% | -3.7% | 0.3% |
Return vs Industry: BAYND underperformed the UK Pharmaceuticals industry which returned -5.5% over the past year.
Return vs Market: BAYND underperformed the UK Market which returned -1.8% over the past year.
Price Volatility
| BAYND volatility | |
|---|---|
| BAYND Average Weekly Movement | 5.6% |
| Pharmaceuticals Industry Average Movement | 8.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: BAYND has not had significant price volatility in the past 3 months.
Volatility Over Time: BAYND's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1863 | 96,931 | Bill Anderson | www.bayer.com |
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.
Bayer Aktiengesellschaft Fundamentals Summary
| BAYND fundamental statistics | |
|---|---|
| Market cap | €26.86b |
| Earnings (TTM) | -€2.94b |
| Revenue (TTM) | €47.64b |
0.6x
P/S Ratio-9.1x
P/E RatioIs BAYND overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BAYND income statement (TTM) | |
|---|---|
| Revenue | €47.64b |
| Cost of Revenue | €19.75b |
| Gross Profit | €27.89b |
| Other Expenses | €30.83b |
| Earnings | -€2.94b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
| Earnings per share (EPS) | -2.99 |
| Gross Margin | 58.55% |
| Net Profit Margin | -6.17% |
| Debt/Equity Ratio | 132.3% |
How did BAYND perform over the long term?
See historical performance and comparisonDividends
0.4%
Current Dividend Yield-4%
Payout RatioDoes BAYND pay a reliable dividends?
See BAYND dividend history and benchmarks| Bayer dividend dates | |
|---|---|
| Ex Dividend Date | Apr 29 2024 |
| Dividend Pay Date | May 02 2024 |
| Days until Ex dividend | 4 days |
| Days until Dividend pay date | 7 days |
Does BAYND pay a reliable dividends?
See BAYND dividend history and benchmarks